Next-Generation Ablation System Treats Atrial Fibrillation
|
By HospiMedica International staff writers Posted on 10 Apr 2019 |

Image: The HeartLight Excalibur Balloon and HeartLight X3 System (Photo courtesy of CardioFocus).
A third-generation technology platform uses laser ablation to perform pulmonary vein isolation (PVI), blocking the abnormal electrical pathways that cause atrial fibrillation (AF).
The CardioFocus (Marlborough, MA, USA) HeartLight X3 System combines direct tissue visualization, titratable laser energy, and compliant balloon technology to enable uninterrupted, high-speed, circumferential lesion creation under direct control of the physician, resulting in consistently reduced procedure times. The system is based on a near infrared (NIR) laser and a deflectable sheath that provides transseptal access to all four pulmonary veins. In a pivotal confirmatory evaluation study, the HeartLight X3 System achieved PVI in just three minutes for a single vein, potentially completing all required ablations in less than 20 minutes.
During the procedure, the HeartLight X3 Balloon is delivered using fluoroscopic guidance via a catheter; once in position, it is inflated. An integrated micro-endoscope is then used to visualize the placement of the balloon relative to the ostium of the vein. The physician can then use the endoscopic image to plan and execute the location of each arc of NIR laser light, placing overlapping arcs of light into the atrial wall around each vein. The scar tissue formed creates a conduction block with just several 20-30 second energy deliveries.
“Our clinical results using the HeartLight X3 System have been outstanding, with unprecedented treatment speed and precise lesion creation,” said study lead investigator Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien (Frankfurt, Germany). “Based on our experience with the device, we feel confident that the HeartLight X3 System is poised to change the way atrial fibrillation ablation is performed in Europe.”
PVI was developed to prevent focal triggers in the pulmonary veins from initiating episodes of AF. The procedure initially involved focal ablation with a catheter directly in the pulmonary veins, but isolating the pulmonary veins by applying ablation energy at their junction with the left atrium was found to be more effective. The PVI procedure is most suitable for patients whose recurring symptomatic episodes of AF that have not been suppressed by anti-arrhythmic drugs, or who do not wish to take long-term anti-arrhythmic or anticoagulation medications.
Related Links:
CardioFocus
Cardioangiologisches Centrum Bethanien
The CardioFocus (Marlborough, MA, USA) HeartLight X3 System combines direct tissue visualization, titratable laser energy, and compliant balloon technology to enable uninterrupted, high-speed, circumferential lesion creation under direct control of the physician, resulting in consistently reduced procedure times. The system is based on a near infrared (NIR) laser and a deflectable sheath that provides transseptal access to all four pulmonary veins. In a pivotal confirmatory evaluation study, the HeartLight X3 System achieved PVI in just three minutes for a single vein, potentially completing all required ablations in less than 20 minutes.
During the procedure, the HeartLight X3 Balloon is delivered using fluoroscopic guidance via a catheter; once in position, it is inflated. An integrated micro-endoscope is then used to visualize the placement of the balloon relative to the ostium of the vein. The physician can then use the endoscopic image to plan and execute the location of each arc of NIR laser light, placing overlapping arcs of light into the atrial wall around each vein. The scar tissue formed creates a conduction block with just several 20-30 second energy deliveries.
“Our clinical results using the HeartLight X3 System have been outstanding, with unprecedented treatment speed and precise lesion creation,” said study lead investigator Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien (Frankfurt, Germany). “Based on our experience with the device, we feel confident that the HeartLight X3 System is poised to change the way atrial fibrillation ablation is performed in Europe.”
PVI was developed to prevent focal triggers in the pulmonary veins from initiating episodes of AF. The procedure initially involved focal ablation with a catheter directly in the pulmonary veins, but isolating the pulmonary veins by applying ablation energy at their junction with the left atrium was found to be more effective. The PVI procedure is most suitable for patients whose recurring symptomatic episodes of AF that have not been suppressed by anti-arrhythmic drugs, or who do not wish to take long-term anti-arrhythmic or anticoagulation medications.
Related Links:
CardioFocus
Cardioangiologisches Centrum Bethanien
Latest Surgical Techniques News
- Ultrasound Technology Aims to Replace Invasive BPH Procedures
- Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
- New Approach Enables Customized Muscle Tissue Without Biomaterial Scaffolds
- Robot-Assisted Brain Angiography Improves Procedural Outcomes
- Brain Mapping Technology Enhances Precision in Brain Tumor Resection
- Handheld Robotic System Expands Options for Total Knee Surgery
- VR Experience Reduces Patient Anxiety Before Kidney Stone Procedure
- Injectable Mini Livers Offer Hope for Patients Awaiting Transplant
- Pulsed Field Ablation Technology Cleared in Europe for Persistent AFib
- AI-Powered Imaging Brings Real-Time Margin Clarity to Breast Cancer Surgery
- Minimally Invasive Device Safely Treats Challenging Brain Aneurysms
- Surgical Robot Makes Complex Liver Tumor Surgery Safer and Less Invasive
- Neurostimulation Implant Reduces Seizure Burden in Drug-Resistant Epilepsy
- Minimally Invasive Procedure Effectively Treats Small Kidney Cancers
- Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal
- Novel Hydrogel Could Become Bone Implant of the Future
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read more
Automated IV Labeling Solution Improves Infusion Safety and Efficiency
Medication administration in high-acuity settings is often complicated by multiple concurrent infusions, making accurate line identification essential. In a 10-hospital intensive care unit study, 60% of... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







